The impact of efflux transporters in the brain on the development of drugs for CNS disorders

被引:111
作者
Taylor, EM [1 ]
机构
[1] NeoTherapeut Inc, Irvine, CA 92618 USA
关键词
D O I
10.2165/00003088-200241020-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The development of drugs to treat disorders of the CNS requires consideration of achievable brain concentrations. Factors that influence the brain concentrations of drugs include the rate of transport into the brain across the blood-brain barrier (BBB), metabolic stability of the drug, and active transport out of the brain by efflux mechanisms. To date, three classes of transporter have been implicated in the efflux of drugs from the brain: multidrug resistance transporters, monocarboxylic acid transporters, and organic ion transporters. Each of the three classes comprises multiple transporters, each of which has multiple substrates, and the combined substrate profile of these transporters includes a large number of commonly used drugs. This system of transporters may therefore provide a mechanism through which the penetration of CNS-targeted drugs into the brain is effectively minimised. The action of these efflux transporters at the 131313 may be reflected in the clinic as the minimal effectiveness of drugs targeted at CNS disorders, including HIV dementia, epilepsy, CNS-based pain, meningitis and brain cancers. Therefore, modulation of these efflux transporters by design of inhibitors and/or design of compounds that have minimal affinity for these transporters may well enhance the treatment of intractable CNS disorders.
引用
收藏
页码:81 / 92
页数:12
相关论文
共 136 条
[1]   Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2 [J].
Abe, T ;
Kakyo, M ;
Sakagami, H ;
Tokui, T ;
Nishio, T ;
Tanemoto, M ;
Nomura, H ;
Hebert, SC ;
Matsuno, S ;
Kondo, H ;
Yawo, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (35) :22395-22401
[2]   Aluminum citrate is transported from brain into blood via the monocarboxylic acid transporter located at the blood-brain barrier [J].
Ackley, DC ;
Yokel, RA .
TOXICOLOGY, 1997, 120 (02) :89-97
[3]   Aluminum transport out of brain extracellular fluid is proton dependent and inhibited by mersalyl acid, suggesting mediation by the monocarboxylate transporter (MCT1) [J].
Ackley, DC ;
Yokel, RA .
TOXICOLOGY, 1998, 127 (1-3) :59-67
[4]  
ADKISON KDK, 1994, J PHARMACOL EXP THER, V268, P797
[5]   Effect of para-aminohippurate on the efflux of valproic acid from the central nervous system of the rabbit [J].
Adkison, KDK ;
Powers, KM ;
Artru, AA ;
Shen, DD .
EPILEPSY RESEARCH, 1996, 23 (02) :95-104
[6]   Altered expression and function of P-glycoprotein (170 kDa), encoded by the MDR 1 gene, in T cell subsets from aging humans [J].
Aggarwal, S ;
Tsuruo, T ;
Gupta, S .
JOURNAL OF CLINICAL IMMUNOLOGY, 1997, 17 (06) :448-454
[7]   Dichotomous development of the organic anion transport protein in liver and choroid plexus [J].
Angeletti, RH ;
Bergwerk, AJ ;
Novikoff, PM ;
Wolkoff, AW .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1998, 275 (03) :C882-C887
[8]   The choroid plexus epithelium is the site of the organic anion transport protein in the brain [J].
Angeletti, RH ;
Novikoff, PM ;
Juvvadi, SR ;
Fritschy, JM ;
Meier, PJ ;
Wolkoff, AW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (01) :283-286
[9]   Blood-brain barrier is involved in the efflux transport of a neuroactive steroid, dehydroepiandrosterone sulfate, via organic anion transporting polypeptide 2 [J].
Asaba, H ;
Hosoya, K ;
Takanaga, H ;
Ohtsuki, S ;
Tamura, E ;
Takizawa, T ;
Terasaki, T .
JOURNAL OF NEUROCHEMISTRY, 2000, 75 (05) :1907-1916
[10]   Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders [J].
Banks, WA .
JOURNAL OF NEUROVIROLOGY, 1999, 5 (06) :538-555